Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

(2018) Jun Luo et al.   EUROPEAN UROLOGY

PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

(2018) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate

(2018) Chun-Peng Liao et al.   ONCOGENE

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

(2018) Howard I. Scher et al.   JAMA Oncology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Persistent androgen receptor addiction in castration-resistant prostate cancer

(2015) Michael T. Schweizer et al.   Journal of Hematology & Oncology

Are androgen receptor variants a substitute for the full-length receptor?

(2015) Ji Lu et al.   Nature Reviews Urology

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition

(2015) Chengfei Liu et al.   PROSTATE

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer

(2014) S Merson et al.   BRITISH JOURNAL OF CANCER

Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis

(2014) Jason Boyang Wu et al.   JOURNAL OF CLINICAL INVESTIGATION

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes

(2014) Ryan R. Gordon et al.   PLoS One

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

(2011) Shikha Gaur et al.   CANCER LETTERS

MAO inhibitors: Risks, benefits, and lore

(2010) M. WIMBISCUS et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Targeting monoamine oxidase A in advanced prostate cancer

(2010) Vincent Flamand et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

(2009) Hongjuan Zhao et al.   BMC Medical Genomics

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

(2009) William P Harris et al.   Nature clinical practice. Urology

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

The Significance of Monoamine Oxidase-A Expression in High Grade Prostate Cancer

(2008) Donna M. Peehl et al.   JOURNAL OF UROLOGY